» Articles » PMID: 7682703

En Bloc Substitution of the Src Homology Region 2 Domain Activates the Transforming Potential of the C-Abl Protein Tyrosine Kinase

Overview
Specialty Science
Date 1993 Apr 15
PMID 7682703
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Src homology region 2 (SH2) domains are present in many proteins involved in signal transduction. In nonreceptor protein tyrosine kinases the SH2 domain has been implicated in regulation of tyrosine kinase activity and in mediating interactions involved in downstream signaling. Different SH2 domains exhibit distinct binding specificities for both phosphotyrosine- and phosphoserine/phosphothreonine-containing proteins. We show that different SH2 domains are not functionally equivalent within the context of the c-ABL1b protooncogene. c-ABL1b, altered by replacement of its SH2 domain with the N-terminal SH2 domain of Ras GTPase-activating protein, exhibited activated transforming capability, caused intracellular tyrosine phosphorylation of p62, and was relocalized from nucleus to cytoplasm. This en bloc substitution apparently uncouples two distinct functions of the SH2 domain so that c-ABL escapes normal regulatory control while it retains the capability to elicit signals that promote transformation. The SH2 domain of the ARG protein tyrosine kinase, which shares high amino acid-sequence homology with the SH2 domain of ABL, was less effective in activating the oncogenic potential of c-ABL. The effects that the N-terminal SH2 domain of Ras GTPase-activating protein has in the context of c-ABL resemble the effects of deleting the SH3 domain. Thus, the SH2 and SH3 domains may have coordinate roles as regulatory control elements within the context of c-ABL.

Citing Articles

Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.

Tannenbaum-Dvir S, Glade Bender J, Church A, Janeway K, Harris M, Mansukhani M Cold Spring Harb Mol Case Stud. 2016; 1(1):a000471.

PMID: 27148571 PMC: 4850889. DOI: 10.1101/mcs.a000471.


Structure, regulation, signaling, and targeting of abl kinases in cancer.

Hantschel O Genes Cancer. 2012; 3(5-6):436-46.

PMID: 23226581 PMC: 3513796. DOI: 10.1177/1947601912458584.


The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Warren D, Heilpern A, Berg K, Rosenberg N J Virol. 2000; 74(10):4495-504.

PMID: 10775585 PMC: 111963. DOI: 10.1128/jvi.74.10.4495-4504.2000.


c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.

Plattner R, Kadlec L, DeMali K, Kazlauskas A, Pendergast A Genes Dev. 1999; 13(18):2400-11.

PMID: 10500097 PMC: 317022. DOI: 10.1101/gad.13.18.2400.


Oncogenic activation of c-ABL by mutation within its last exon.

Goga A, McLaughlin J, Pendergast A, Parmar K, Muller A, Rosenberg N Mol Cell Biol. 1993; 13(8):4967-75.

PMID: 8336729 PMC: 360140. DOI: 10.1128/mcb.13.8.4967-4975.1993.


References
1.
Ben-Neriah Y, Bernards A, Paskind M, Daley G, Baltimore D . Alternative 5' exons in c-abl mRNA. Cell. 1986; 44(4):577-86. DOI: 10.1016/0092-8674(86)90267-9. View

2.
Lebkowski J, DuBridge R, Antell E, Greisen K, Calos M . Transfected DNA is mutated in monkey, mouse, and human cells. Mol Cell Biol. 1984; 4(10):1951-60. PMC: 369011. DOI: 10.1128/mcb.4.10.1951-1960.1984. View

3.
Shtivelman E, Lifshitz B, Gale R, Roe B, Canaani E . Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986; 47(2):277-84. DOI: 10.1016/0092-8674(86)90450-2. View

4.
Sadowski I, Stone J, Pawson T . A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol. 1986; 6(12):4396-408. PMC: 367222. DOI: 10.1128/mcb.6.12.4396-4408.1986. View

5.
Kmiecik T, Shalloway D . Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell. 1987; 49(1):65-73. DOI: 10.1016/0092-8674(87)90756-2. View